Beactica Therapeutics AB
Beactica Therapeutics is a Swedish precision oncology company developing first-in-class small molecule degraders for cancers with high unmet need, including the FDA-designated orphan drug BEA-17 for glioblastoma. Its Eclipsor™ platform combines allosteric modulation with targeted protein degradation to drug previously 'undruggable' targets.
- Company typePrivate
- Founded2006
- HeadquartersUppsala, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Beactica Therapeutics AB does
Beactica Therapeutics AB is a Swedish precision oncology company founded in 2006 as a spin-out from Uppsala University, developing first-in-class small molecule therapeutics for cancers with significant unmet medical need. The company's core asset is the proprietary Eclipsor™ platform, which combines allosteric modulation with targeted protein degradation (TPD) to address proteins historically considered 'undruggable' by conventional small-molecule approaches. Its lead clinical-stage program, BEA-17, is a first-in-class LSD1-CoREST degrader for glioblastoma that has received FDA Orphan Drug Designation and simultaneous immune-activation mechanisms (antigen presentation restoration, viral mimicry induction, tumor microenvironment reprogramming). A second disclosed program, P65-047, is a cereblon-recruiting TEAD degrader that overcomes KRAS inhibitor resistance in non-small cell lung cancer, with demonstrated in vivo tumor regression and KRAS inhibitor resensitization. The pipeline is supported by an SPR biosensor-based screening engine that was originally commercialized as a fragment-based drug discovery service.
The company operates a hybrid business model spanning proprietary drug development, partner-validated drug discovery services, and non-dilutive grant funding. Historically, service revenue has been generated through long-term collaborations with major pharmaceutical companies including Sanofi (extended framework agreement), Boehringer Ingelheim (FBDD work contributing to afatinib insights), Janssen Research & Development, AstraZeneca (via Arrow Therapeutics), Medivir, Almac Discovery, and GE Healthcare (SPR instrument co-development with Uppsala University). Co-development partnerships span KU Leuven (GLIOBREAK project for BEA-17), Dong-A ST (concluded 2022), and academic collaborations with Uppsala University's SciLifeLab DDD Platform and the University of Texas M.D. Anderson Cancer Center (P65-047). The company has secured multiple non-dilutive grants including the EUR 2.5 million European Innovation Council Transition grant (February 2026) and earlier EU Framework Programme awards aggregating over EUR 12.5 million across consortia targeting CNS receptors, influenza (FluCure), and brain disease networks (NeuroCypres, BrainTrain, SynSys).
Beactica is privately held, headquartered in Uppsala Business Park, Sweden, with 11-50 employees. The company has received Clarivate recognition as one of six 'Protein Degrader Companies to Watch 2025' and was previously ranked fifth among Deloitte Sweden's fastest-growing technology companies (Technology Rising Star, >500% three-year revenue growth). Strategic focus has shifted from a primarily service-oriented model toward clinical-stage proprietary development, with BEA-17 advancing through IND-enabling studies and P65-047 building pre-clinical momentum toward KRAS-resistant NSCLC.
Beactica Therapeutics AB firmographics
Firmographics- Name
- Beactica Therapeutics AB
- Legal name
- Beactica Therapeutics AB
- Website
- https://beactica.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Beactica Therapeutics is a Swedish precision oncology company developing first-in-class small molecule degraders for cancers with high unmet need, including the FDA-designated orphan drug BEA-17 for glioblastoma. Its Eclipsor™ platform combines allosteric modulation with targeted protein degradation to drug previously 'undruggable' targets.
- Ownership category
- akta.pro rank
Beactica Therapeutics AB industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where Beactica Therapeutics AB is headquartered
LocationHeadquarters
- HQ city
- Uppsala
- HQ country
- Sweden
- HQ region
- Europe
Offices2 records
Markets served
Beactica Therapeutics AB business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Proprietary Drug Development: Advancing proprietary therapeutic programs (BEA-17, P65-047) through clinical development to deliver value to patients and shareholders
- Drug Discovery Services: Partner-validated drug discovery technology offered through service agreements and collaborations with pharmaceutical companies
- Non-Dilutive Grant Funding: EUR 2.5 million EIC grant for GLIOBREAK project covering 100% of project costs for BEA-17 development
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Beactica Therapeutics AB product offering
Product offeringCore offering
Beactica Therapeutics AB discovers and develops small molecule precision oncology therapeutics, anchored by its proprietary Eclipsor™ platform which enables allosteric modulators and targeted protein degraders (TPD). Its lead pipeline assets are BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma (FDA Orphan Drug Designation), and P65-047, a cereblon-recruiting TEAD degrader for KRAS inhibitor-resistant NSCLC. The company also monetizes the underlying platform through fragment-based drug discovery services and SPR biosensor screening partnerships with global pharma.
Product overview
Beactica Therapeutics AB is a precision medicine company developing novel small molecule therapeutics to treat life-threatening cancers with significant unmet clinical need. The company's offering consists of the Eclipsor™ platform, which enables development of allosteric modulators and targeted protein degraders, and a pipeline of proprietary drug candidates including BEA-17 (LSD1-CoREST degrader for glioblastoma) and P65-047 (TEAD degrader for KRAS inhibitor resistance in NSCLC).
Differentiator
Problem solved
Functional benefit
Brands
- Eclipsor™: Targeted protein degradation platform enabling development of allosteric modulators and targeted protein degraders
Products and services
- Eclipsor™ Platform Beactica's proprietary technology platform that combines allosteric modulation and targeted protein degradation (TPD) to enable the discovery of small molecule therapeutics against proteins previously considered 'undruggable'. The platform is leveraged both internally for Beactica's proprietary pipeline and offered to pharmaceutical partners through drug discovery collaborations.
- BEA-17 (LSD1-CoREST Degrader) First-in-class LSD1-CoREST targeted protein degrader being developed by Beactica for the treatment of glioblastoma. It degrades the LSD1-CoREST complex to restore antigen presentation, induce viral mimicry responses, and reprogram the tumour microenvironment, and has received FDA Orphan Drug Designation.
- P65-047 (TEAD Degrader) Cereblon-recruiting TEAD degrader being developed by Beactica to overcome KRAS inhibitor resistance in NSCLC. It eliminates resistance-mediating Hippo pathway co-factors such as VGLL3, displays robust in vivo tumour regression as monotherapy, and re-sensitises resistant NSCLC models to KRAS inhibitors such as MRTX1133 and MRTX849.
- Fragment-Based Drug Discovery Services Drug discovery service offering in which Beactica applies its SPR biosensor-based fragment screening and Eclipsor™ chemistry platform, on a paid service or co-development basis, to identify leads for pharmaceutical partners against challenging protein targets (CNS proteins, kinases, proteases, antivirals, oncology targets).
Quantifiable outcome
- First-in-class LSD1-CoREST degrader achieving simultaneous immune activation mechanisms
- +2 more outcomes
Companies that use Beactica Therapeutics AB
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles1 record
Beactica Therapeutics AB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Beactica Therapeutics AB partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core, minor and major.
- University of Texas M. D. Anderson Cancer CentercoreCollaboration on TEAD degrader program P65-047, contributing research for AACR late-breaking presentations on KRAS inhibitor resistance mechanisms in NSCLC.
- KU Leuvencore30-month GLIOBREAK project to advance BEA-17 (first-in-class LSD1-CoREST degrader) towards clinical trials for glioblastoma treatment. EUR 2.5 million EIC grant covering 100% of project costs for IND-enabling studies and regulatory submissions.
- BioArcticminorBioArctic to evaluate Beactica's Eclipsor™ technology for potential applications in neurodegenerative diseases.
- National Center for Advancing Translational Sciences (NCATS)minorCollaboration with NIH's NCATS for advancing translational sciences initiatives.
- OscotecminorOncology collaboration concluded by mutual agreement in April 2023.
- Dong-A STmajorLicense and collaboration agreement to develop new cancer treatments. Expanded research agreement in 2019. Key milestone achieved in December 2019. Collaboration concluded in September 2022 by mutual agreement.
- VIB and CD3minorDrug discovery alliance targeting inflammatory diseases with VIB (Flemish Institute for Biotechnology) and CD3 (Centre for Drug Design and Discovery).
- SanofimajorThree-year extension agreement (original five-year framework agreement signed 2018) for ongoing drug discovery collaboration.
- Uppsala University and SciLifeLab DDD PlatformminorGlioblastoma research collaboration with Uppsala University and Drug Discovery and Development Platform at SciLifeLab.
- MedivirminorDrug discovery collaboration targeting disease-relevant protease of therapeutic interest to Medivir.
- Boehringer IngelheimmajorExpanded collaboration since 2008 for fragment-based discovery against oncology-relevant kinases. Contributed to understanding of afatinib (Giotrif).
- Almac DiscoveryminorFragment-based drug discovery agreement against cancer targets of therapeutic interest to Almac.
- Janssen Research & DevelopmentmajorFragment-based drug discovery agreement against undisclosed CNS targets. Extended in 2012 for additional projects.
- FluCure Consortium (EU 7th Framework)minorEU-funded project developing small-molecule influenza therapeutics targeting viral ribonucleoprotein complex. Partners include Vironova AB and Pike Pharma GmbH.
- Cubist PharmaceuticalsminorDrug discovery agreement targeting multi-component proteins from pathogenic bacteria for next-generation anti-bacterials.
- GE HealthcaremajorResearch collaboration with GE Healthcare and Uppsala University to develop next-generation Biacore SPR instruments and applications for fragment-based drug discovery.
- Arrow TherapeuticsminorDrug discovery collaboration applying Beactica's characterization technology to Arrow compounds against antiviral targets. (Acquired by AstraZeneca 2007)
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Beactica Therapeutics AB competitors and assessment
Company assessmentBroad incumbents
- Arvinas: Public US-based pioneer of PROTAC targeted protein degradation with clinical-stage assets (vepdegestrant, ARV-102). Directly comparable as a TPD platform company targeting 'undruggable' proteins, but significantly larger and more advanced than Beactica.
- Kymera Therapeutics: Clinical-stage US biotech developing heterobifunctional degraders across immunology and oncology. Directly comparable as a TPD platform peer, with multiple Phase 1 programs and major pharma partnerships (Sanofi).
- C4 Therapeutics: Clinical-stage US biotech developing TORPEDO platform degraders in oncology. Comparable in TPD approach with partnered assets (Bevangen/Calgene) and similar target classes to Beactica's Eclipsor™ programs.
- Monte Rosa Therapeutics: Clinical-stage US biotech developing molecular glue degraders with a particular focus on oncology and immunology. Comparable as a platform TPD company with similar scientific ambitions around previously undruggable targets.
- Nurix Therapeutics: Clinical-stage US biotech developing ligase-modulating drugs including degraders, with major partnerships (Sanofi, Gilead). Comparable as a TPD platform peer with deep pharma collaboration model similar to Beactica's.
Direct peers
- Foghorn Therapeutics: US clinical-stage biotech targeting chromatin regulatory systems, including an LSD1 program (FHD-286) in oncology. Most directly comparable to Beactica's BEA-17 program targeting the LSD1-CoREST complex for glioblastoma and AML.
- Captor Therapeutics: European (Polish) clinical-stage TPD biotech developing targeted protein degraders for cancer and autoimmune diseases. Closest European size-and-stage comparable to Beactica, with a similar platform-based business model.
Regional players
- BioArctic: Public Swedish biotech developing neurodegenerative disease treatments. Comparable as a regional peer; Beactica's Eclipsor™ platform is currently being evaluated by BioArctic for potential neurodegenerative applications.
- Medivir: Swedish clinical-stage biotech focused on oncology (fostrox). Comparable regional peer and historical Beactica partner (fragment-based drug discovery collaboration); CEO Per Källblad's former employer.
Emerging players
- Exscientia: European AI-driven precision medicine company with pharma partnerships. Comparable as a tech-enabled drug discovery platform peer with similar pharma partnership-driven business model and European base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Beactica Therapeutics AB social profiles
Digital presenceBeactica Therapeutics AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
Beactica Therapeutics AB leadership team
Management profileNumber of profiles
Profiles11 records
Beactica Therapeutics AB funding detail
Funding detailFunding overview
Funding rounds10 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Beactica Therapeutics AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Beactica Therapeutics AB
What does Beactica Therapeutics AB do?
Beactica Therapeutics AB discovers and develops small molecule precision oncology therapeutics, anchored by its proprietary Eclipsor™ platform which enables allosteric modulators and targeted protein degraders (TPD). Its lead pipeline assets are BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma (FDA Orphan Drug Designation), and P65-047, a cereblon-recruiting TEAD degrader for KRAS inhibitor-resistant NSCLC. The company also monetizes the underlying platform through fragment-based drug discovery services and SPR biosensor screening partnerships with global pharma.
Is Beactica Therapeutics AB a public or private company?
Beactica Therapeutics AB is a private company. It is classified as venture growth investor backed and is currently operating.
When was Beactica Therapeutics AB founded?
Beactica Therapeutics AB was founded in 2006. It employs 11 to 50 people.
Where is Beactica Therapeutics AB based?
Beactica Therapeutics AB is headquartered in Uppsala, Sweden, in the Europe region.
How does Beactica Therapeutics AB make money?
Three revenue lines are on record. Proprietary Drug Development is the primary driver. The others are drug Discovery Services and non-Dilutive Grant Funding.
Who are Beactica Therapeutics AB's main competitors?
Broad incumbents on record are Arvinas, Kymera Therapeutics, C4 Therapeutics, Monte Rosa Therapeutics and Nurix Therapeutics. Direct peers are Foghorn Therapeutics and Captor Therapeutics. Regional players are BioArctic and Medivir. Exscientia is listed as an emerging player.
Does Beactica Therapeutics AB have an API?
No public API is recorded for Beactica Therapeutics AB.
What industry is Beactica Therapeutics AB in?
Beactica Therapeutics AB's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 541714 and its SIC code is 2834.